Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.9346
+0.0202 (2.21%)
At close: Jun 23, 2026, 4:00 PM EDT
0.9500
+0.0154 (1.65%)
After-hours: Jun 23, 2026, 7:22 PM EDT
Invivyd Revenue
Invivyd had revenue of $13.74M in the quarter ending March 31, 2026, with 21.59% growth. This brings the company's revenue in the last twelve months to $55.87M, up 52.27% year-over-year. In the year 2025, Invivyd had annual revenue of $53.43M with 110.47% growth.
Revenue (ttm)
$55.87M
Revenue Growth
+52.27%
P/S Ratio
4.93
Revenue / Employee
$457,918
Employees
122
Market Cap
275.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.43M | 28.04M | 110.47% |
| Dec 31, 2024 | 25.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| Bicycle Therapeutics | 63.50M |
| Lineage Cell Therapeutics | 14.78M |
| Surrozen | 7.49M |
| Cartesian Therapeutics | 1.78M |
| SAB Biotherapeutics | 114.70K |
| Lyell Immunopharma | 31.00K |
IVVD News
- 7 days ago - Invivyd completes enrollment of LIBERTY clinical trial - TheFly
- 7 days ago - Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine - GlobeNewsWire
- 14 days ago - Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration - GlobeNewsWire
- 15 days ago - Invivyd Transcript: H.C. Wainwright “HCW @ Home” Series - Transcripts
- 20 days ago - Invivyd Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 20 days ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Invivyd completes enrollment in DECLARATION trial - TheFly
- 22 days ago - Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID - GlobeNewsWire